News
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback